Vasey P
Int J Oncol. 1993 Apr;2(4):677-81. doi: 10.3892/ijo.2.4.677.
The anthracycline class of antitumour agents have the widest spectrum of activity of all drugs used to treat malignant disease. Consequently they are ubiquitous in their use worldwide, but are not without problems. The abrogation of cardiac toxicity and the development of drug resistance has been attempted by modifying the molecule chemically, producing over 1000 structural analogues since the discovery of Daunorubicin in the late 1950's. This review charts this developmental process and points to the possible future of this important class of drugs.
蒽环类抗肿瘤药物在用于治疗恶性疾病的所有药物中具有最广泛的活性谱。因此，它们在全球范围内广泛使用，但并非没有问题。自20世纪50年代末发现柔红霉素以来，人们一直试图通过化学修饰分子来消除心脏毒性并克服耐药性，已经产生了1000多种结构类似物。这篇综述梳理了这一发展过程，并指出了这类重要药物可能的未来。
